MedPath

Bivalirudin

These highlights do not include all the information needed to use BIVALIRUDIN FOR INJECTION safely and effectively. See full prescribing information for BIVALIRUDIN FOR INJECTION. BIVALIRUDIN for injection, for intravenous useInitial U.S. Approval: 2000

Approved
Approval ID

42aa2630-83d6-433d-8277-0f672cf8d71d

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 20, 2023

Manufacturers
FDA

Avenacy, Inc.

DUNS: 119060628

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

bivalirudin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code83634-400
Application NumberANDA210031
Product Classification
M
Marketing Category
C73584
G
Generic Name
bivalirudin
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateDecember 18, 2023
FDA Product Classification

INGREDIENTS (3)

bivalirudinActive
Quantity: 250 mg in 1 1
Code: TN9BEX005G
Classification: ACTIB
mannitolInactive
Code: 3OWL53L36A
Classification: IACT
sodium hydroxideInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Bivalirudin - FDA Drug Approval Details